The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating your cancer when combined with other cancer drugs, compared to the standard of care for people with breast cancer.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
-
ERM Project ID
91557
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part
Patients with breast cancer which is HER2-negative type that has progressed, or spread to other parts of your body (metastatic).
What is involved for you
Your tumour tissue will be tested for a certain type of genetic mutation, which may make your tumour more sensitive to certain types of treatment. The result of this genetic test will partially determine which of the experimental medicines you will receive. You will receive the standard of care therapy for your tumour type, as well as the possible addition of the investigational medicine Gedatolisib. You will come into the clinic every 1-2 weeks to receive treatment via intravenous injection into a vein, oral tablets or an intramuscular injection. While in the clinic you will also receive a physical exam, blood test and regular tumour assessments via scans.
